Chronic Kidney Disease Trials Could Gain New Surrogate Endpoints
Executive Summary
FDA is considering the use of 30% and 40% reductions in glomerular filtration rate as surrogate endpoints for the development of kidney failure in clinical trials; the current standard is 50%.